No Data
TRANSCENTA-B (06628.HK) repurchased 0.01 million shares on January 10.
Gelonghui January 10th丨TRANSCENTA-B (06628.HK) announced that on January 10th, it spent HKD 6,100 to repurchase 0.01 million shares.
TRANSCENTA-B (06628.HK) spent 0.06 million HKD to repurchase 0.1 million shares on January 9.
On January 9, Legend Holdings Group-B (06628.HK) announced that it spent 0.06 million Hong Kong dollars to repurchase 0.1 million shares.
TRANSCENTA-B (06628.HK) spent HKD 9,409.6 to repurchase 0.016 million shares on January 3.
Gelonghui, January 3rd丨TRANSCENTA-B (06628.HK) announced that on January 3rd, it spent 9,409.6 Hong Kong dollars to repurchase 0.016 million shares.
TRANSCENTA-B (06628.HK) spent 0.0902 million HKD to repurchase 0.147 million shares on December 31.
Gelonghui, on December 31, announced that TRANSCENTA-B (06628.HK) spent 0.0902 million HKD to repurchase 0.147 million shares, with a repurchase price ranging from 0.59 to 0.63 HKD per share.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
TRANSCENTA-B (06628) announced the latest Business progress on its new LIV-1 ADCs for the antitumor effects in models of triple-negative breast cancer at the 2024 SABCS.
TRANSCENTA-B (06628) announced that the 2024 San Antonio Breast Cancer Symposium (SABCS)...
No Data
